A groundbreaking study from South Africa explored the use of Gardasil® as an adjunctive therapy for juvenile-onset recurrent respiratory papillomatosis (JoRRP). Researchers observed substantial reductions in disease severity, longer intervals between surgeries, and lower tracheostomy rates, offering new evidence supporting the potential role of HPV vaccination in established RRP cases.

RRPF strongly opposes the adoption of single-dose HPV vaccination as a replacement for the multi-dose regimen in the United States. The evidence supporting "One Is Enough" applies to cervical cancer prevention and cannot be extended to HPV 6/11-driven diseases like RRP.

RRPF has been nominated for the inaugural Prix Galien Patient First Award in Honor of Michael J. Fox, recognizing our work to bring patient voices into the regulatory record. The winner will be announced October 29 in New York City.

A new study comparing patient experiences with surgery and systemic bevacizumab found that 83% of patients preferred bevacizumab and reported better voice, breathing, less pain, and improved mental health. Here's what the research found.

A new clinical trial led by Dr. Sarah Pai is investigating combination immunotherapy for adults with RRP that has spread to the lungs. Learn about the study and how to participate.

Dr. Aaron Friedman joins the BackTable ENT podcast to discuss immune-directed therapy for RRP, including the FDA-approved PAPZIMEOS vaccine and what clinical trial data reveal about durable treatment responses in adults.

A newly published study in The Laryngoscope draws on data from the RRPF/CoRDS Patient Registry to quantify what our community has long known: RRP impacts far more than the airway. Here's what the research found.

After years of advocacy and research, the first patients have now received doses of Papzimeos. RRPF President Kim McClellan reflects on what this historic moment means for our community.

RRPF has published a new position statement outlining an evidence-based management algorithm for adults with RRP, developed by key opinion leaders with direct patient input.

INOVIO's Biologics License Application for INO-3017 has been accepted by the FDA. RRPF shares an update on the review process and our advocacy for the accelerated approval pathway.

INOVIO announced that the FDA has accepted its Biologics License Application for INO-3107 for review as a potential treatment for adults with RRP. Here's what this milestone means for our community.

The RRPF invited Dr. Clint Allen, Dr. Simon Best, Dr. Geoffrey Young, and Precigen to our webinar series to chat about Papzimeos and answer a few of the questions from our RRP community.

INOVIO announced it has completed the rolling submission of its Biologics License Application for INO-3107. RRPF President Kim McClellan shares what this milestone means for our community.

RRPF President, Kim McClellan, was recently interviewed for the 2026 International Drug Repurposing Conference. Kim's understanding of the RRP patient journey is valuable beyond measure as she tirelessly advocates for you and your loved ones every day.

The FDA has approved Papzimeos, the first and only treatment for adults with RRP. RRPF celebrates this historic milestone and reflects on what it means for our community.